Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease

Area of Science:

• Nephrology
• Mitochondrial Biology
• Oxidative Stress Research

Background:

• Chronic kidney disease (CKD) is a growing global health burden, projected as the fifth leading cause of death by 2040.
• Mitochondrial dysfunction and oxidative stress are key mechanisms linking acute kidney injury (AKI) to CKD progression.
• Existing treatments for kidney diseases lack efficacy in addressing underlying mitochondrial pathology.

Purpose of the Study:

• To review the role of mitochondrial dysfunction and oxidative stress in AKI and CKD.
• To discuss novel therapeutic strategies targeting mitochondria for kidney diseases.
• To identify barriers and propose future research milestones for mitochondria-targeted therapies.

Main Methods:

• Literature review of studies on mitochondrial dysfunction in various AKI and CKD models.
• Analysis of the role of key mitochondrial regulators like PGC-1α and TFEB.
• Assessment of the clinical development status of mitochondria-targeted therapeutics.

Main Results:

• Mitochondrial dysfunction is evident across diverse AKI (nephrotoxicity, cytokine storm, ischemia-reperfusion) and CKD (diabetic kidney disease, glomerulopathies) models.
• Mitochondria-related transcriptional regulators (PGC-1α, TFEB) and CPT1A play critical roles in kidney disease.
• Clinical development of mitochondria-targeted therapies is ongoing but hindered by a lack of diagnostic tools.

Conclusions:

• Mitochondrial dysfunction and oxidative stress are central to kidney injury and disease progression.
• Targeting mitochondria presents a promising therapeutic avenue for AKI and CKD.
• Further research is needed to develop clinical diagnostics for monitoring renal mitochondrial health and treatment response.